Τετάρτη 5 Απριλίου 2017

AACR 2017: Mechanism of PD-1/lenvatinib combo exposed, improving CR in mouse models

Research regarding a mechanism of action that leads to increased anti-tumour activity in mouse models dosed with a combination of lenvatinib mesylate and an anti-mouse PD-1 antibody has been presented at the American Association for Cancer Research...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2o2jPtG
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις